Skip to main content
Top
Published in: Current Hypertension Reports 3/2013

01-06-2013 | Therapeutic Trials (G Mancia, Section Editor)

Heart Rate and the Cardiometabolic Risk

Author: Paolo Palatini

Published in: Current Hypertension Reports | Issue 3/2013

Login to get access

Abstract

Resting heart rate is a well recognized marker of autonomic nervous system tone, and in many population studies has been found to be a significant correlate of blood pressure, increased body mass index, and metabolic disturbances. This association is particularly striking in patients with hypertension or diabetes, and cardiovascular morbidity related to high heart rate in these conditions seems to depend mainly on the clustering of these risk factors. The prospective relationship between tachycardia and metabolic abnormalities found in longitudinal studies indicates that the adrenergic overdrive is the cause rather than the consequence of the insulin resistance state. Findings from observational studies and clinical trials have shown that heart rate measured during the follow-up provides prognostic information over and above heart rate measured at baseline, whereas the predictive value of heart rate measured out of the office is still debated. Antihypertensive drugs that decrease blood pressure and heart rate through a reduction of the sympathetic outflow may be more beneficial in clinical situations characterized by heightened sympathetic activity associated to insulin resistance.
Literature
1.
go back to reference Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis. 2009;52:46–60.PubMedCrossRef Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis. 2009;52:46–60.PubMedCrossRef
2.
go back to reference Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol. 2007;96:585–92.PubMedCrossRef Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol. 2007;96:585–92.PubMedCrossRef
3.
go back to reference Palatini P, Benetos A, Grassi G, European Society of Hypertension, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens. 2006;24:603–10.PubMedCrossRef Palatini P, Benetos A, Grassi G, European Society of Hypertension, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens. 2006;24:603–10.PubMedCrossRef
4.
go back to reference Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8:369–79.PubMedCrossRef Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8:369–79.PubMedCrossRef
5.
go back to reference • Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension. 2011;58:745–50. This article summarizes the most recent information on the clinical significance of elevated heart rate in hypertension. In particular, it provides an update of the predictive capacity of heart rate for cardiovascular mortality in the most recent clinical trials in hypertensive patients. PubMedCrossRef • Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension. 2011;58:745–50. This article summarizes the most recent information on the clinical significance of elevated heart rate in hypertension. In particular, it provides an update of the predictive capacity of heart rate for cardiovascular mortality in the most recent clinical trials in hypertensive patients. PubMedCrossRef
6.
go back to reference Julius S, Valentini M, Palatini P. Overweight and hypertension: a two-way street? Hypertension. 2000;35:807–13.PubMedCrossRef Julius S, Valentini M, Palatini P. Overweight and hypertension: a two-way street? Hypertension. 2000;35:807–13.PubMedCrossRef
7.
go back to reference Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25:909–20.PubMedCrossRef Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25:909–20.PubMedCrossRef
8.
go back to reference • Grassi G, Arenare F, Quarti-Trevano F, et al. Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome. Prog Cardiovasc Dis. 2009;52:31–7. This article reviews the evidence for increased sympathetic activity in hypertension and highlights the role of the autonomic nervous system dysfunction as a determinant of metabolic disturbances. PubMedCrossRef • Grassi G, Arenare F, Quarti-Trevano F, et al. Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome. Prog Cardiovasc Dis. 2009;52:31–7. This article reviews the evidence for increased sympathetic activity in hypertension and highlights the role of the autonomic nervous system dysfunction as a determinant of metabolic disturbances. PubMedCrossRef
9.
go back to reference Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep. 2001;3 Suppl 1:S3–9.PubMedCrossRef Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep. 2001;3 Suppl 1:S3–9.PubMedCrossRef
10.
go back to reference Palatini P, Casiglia E, Pauletto P, et al. Relationship of tachycardia with high blood pressure and metabolic abnormalities. A Study with Mixture Analysis in three Populations. Hypertension. 1997;30:1267–73.PubMedCrossRef Palatini P, Casiglia E, Pauletto P, et al. Relationship of tachycardia with high blood pressure and metabolic abnormalities. A Study with Mixture Analysis in three Populations. Hypertension. 1997;30:1267–73.PubMedCrossRef
11.
go back to reference Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40–7.PubMedCrossRef Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40–7.PubMedCrossRef
12.
go back to reference Gilardini L, Parati G, Sartorio A, et al. Sympathoadrenergic and metabolic factors are involved in ambulatory blood pressure rise in childhood obesity. J Hum Hypertens. 2008;22:75–82.PubMedCrossRef Gilardini L, Parati G, Sartorio A, et al. Sympathoadrenergic and metabolic factors are involved in ambulatory blood pressure rise in childhood obesity. J Hum Hypertens. 2008;22:75–82.PubMedCrossRef
13.
go back to reference Perlini S, Naditch-Brule L, Farsang C, et al. Pulse pressure and heart rate in patients with metabolic syndrome across Europe: insights from the GOOD survey. J Hum Hypertens. 2012. doi:10.1038/jhh.2012.61. Perlini S, Naditch-Brule L, Farsang C, et al. Pulse pressure and heart rate in patients with metabolic syndrome across Europe: insights from the GOOD survey. J Hum Hypertens. 2012. doi:10.​1038/​jhh.​2012.​61.
14.
go back to reference Charakida M, Jones A, Falaschetti E, et al. Childhood obesity and vascular phenotypes: a population study. J Am Coll Cardiol. 2012;60:2643–50.PubMedCrossRef Charakida M, Jones A, Falaschetti E, et al. Childhood obesity and vascular phenotypes: a population study. J Am Coll Cardiol. 2012;60:2643–50.PubMedCrossRef
15.
go back to reference Yano Y, Haimoto H, Hoshide S, et al. Evening heart rate measured at home is associated with visceral obesity and abnormal fat distribution in patients with hypertension. Am J Hypertens. 2011;24:783–8.PubMedCrossRef Yano Y, Haimoto H, Hoshide S, et al. Evening heart rate measured at home is associated with visceral obesity and abnormal fat distribution in patients with hypertension. Am J Hypertens. 2011;24:783–8.PubMedCrossRef
16.
go back to reference Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–80.PubMedCrossRef Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–80.PubMedCrossRef
17.
go back to reference Liang J, Li Y, Zhou N, et al. Synergistic effects of serum uric Acid and cardiometabolic risk factors on early stage atherosclerosis: the cardiometabolic risk in chinese study. PLoS One. 2012;7:e51101.PubMedCrossRef Liang J, Li Y, Zhou N, et al. Synergistic effects of serum uric Acid and cardiometabolic risk factors on early stage atherosclerosis: the cardiometabolic risk in chinese study. PLoS One. 2012;7:e51101.PubMedCrossRef
18.
go back to reference Redon J, Cifkova R, Laurent S, Scientific Council of the European Society of Hypertension, et al. The metabolic syndrome in hypertension: European Society of Hypertension position statement. J Hypertens. 2008;26:1891–900.PubMedCrossRef Redon J, Cifkova R, Laurent S, Scientific Council of the European Society of Hypertension, et al. The metabolic syndrome in hypertension: European Society of Hypertension position statement. J Hypertens. 2008;26:1891–900.PubMedCrossRef
19.
go back to reference Shigetoh Y, Adachi H, Yamagishi S, et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertens. 2009;22:151–5.PubMedCrossRef Shigetoh Y, Adachi H, Yamagishi S, et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertens. 2009;22:151–5.PubMedCrossRef
20.
go back to reference • Palatini P, Mos L, Santonastaso M, et al. Resting heart rate as a predictor of body weight gain in the early stage of hypertension. Obesity. 2011;19:618–23. This study provides evidence for a longitudinal connection between baseline heart rate and risk of obesity and shows that also heart rate measured during the follow-up may influence body weight gain. PubMedCrossRef • Palatini P, Mos L, Santonastaso M, et al. Resting heart rate as a predictor of body weight gain in the early stage of hypertension. Obesity. 2011;19:618–23. This study provides evidence for a longitudinal connection between baseline heart rate and risk of obesity and shows that also heart rate measured during the follow-up may influence body weight gain. PubMedCrossRef
21.
22.
go back to reference Palatini P, Vriz O, Nesbitt S, et al. Parental hemodynamic circulation predicts insulin resistance in offspring. The Tecumseh Offspring Study. Hypertension. 1999;33:769–74.PubMedCrossRef Palatini P, Vriz O, Nesbitt S, et al. Parental hemodynamic circulation predicts insulin resistance in offspring. The Tecumseh Offspring Study. Hypertension. 1999;33:769–74.PubMedCrossRef
23.
go back to reference Palatini P, Majahalme S, Amerena J, et al. Determinants of left ventricular structure and mass in young subjects with sympathetic over-activity. The Tecumseh Offspring Study. J Hypertens. 2000;18:769–75. Palatini P, Majahalme S, Amerena J, et al. Determinants of left ventricular structure and mass in young subjects with sympathetic over-activity. The Tecumseh Offspring Study. J Hypertens. 2000;18:769–75.
24.
go back to reference Palatini P, Longo D, Zaetta V, et al. Evolution of blood pressure and cholesterol in stage 1 hypertension: role of autonomic nervous system activity. J Hypertens. 2006;24:1375–81.PubMedCrossRef Palatini P, Longo D, Zaetta V, et al. Evolution of blood pressure and cholesterol in stage 1 hypertension: role of autonomic nervous system activity. J Hypertens. 2006;24:1375–81.PubMedCrossRef
25.
go back to reference Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010;141:122–31.PubMedCrossRef Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010;141:122–31.PubMedCrossRef
26.
go back to reference Kannel WB, Brand N, Skinner Jr JJ, et al. The relation of adiposity to blood pressure and development of hypertension. Ann Intern Med. 1967;67:48–59.PubMedCrossRef Kannel WB, Brand N, Skinner Jr JJ, et al. The relation of adiposity to blood pressure and development of hypertension. Ann Intern Med. 1967;67:48–59.PubMedCrossRef
27.
go back to reference Valentini M, Julius S, Palatini P, et al. Attenuation of hemodynamic metabolic and energy expenditure responses to isoproterenol in patients with hypertension. J Hypertens. 2004;22:1999–2006.PubMedCrossRef Valentini M, Julius S, Palatini P, et al. Attenuation of hemodynamic metabolic and energy expenditure responses to isoproterenol in patients with hypertension. J Hypertens. 2004;22:1999–2006.PubMedCrossRef
28.
go back to reference Stettler C, Bearth A, Allemann S, et al. QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. Diabetologia. 2007;50:186–94.PubMedCrossRef Stettler C, Bearth A, Allemann S, et al. QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. Diabetologia. 2007;50:186–94.PubMedCrossRef
29.
go back to reference Linnemann B, Janka HU. Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. Exp Clin Endocrinol Diabetes. 2003;111:215–22.PubMedCrossRef Linnemann B, Janka HU. Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. Exp Clin Endocrinol Diabetes. 2003;111:215–22.PubMedCrossRef
30.
go back to reference Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications. 2003;17:169–78.PubMedCrossRef Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications. 2003;17:169–78.PubMedCrossRef
31.
go back to reference Anselmino M, Ohrvik J, Ryden L. Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2010;31:3040–5.PubMedCrossRef Anselmino M, Ohrvik J, Ryden L. Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2010;31:3040–5.PubMedCrossRef
32.
go back to reference Carnethon MR, Yan L, Greenland P, Garside DB, Dyer AR, Metzger B, et al. Resting heart rate in middle age and diabetes development in older age. Diabetes Care. 2008;31:335–9.PubMedCrossRef Carnethon MR, Yan L, Greenland P, Garside DB, Dyer AR, Metzger B, et al. Resting heart rate in middle age and diabetes development in older age. Diabetes Care. 2008;31:335–9.PubMedCrossRef
33.
go back to reference • Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia. 2012;55:1283–90. This is the most recent prospective study on the predictive capacity of heart rate for mortality in a diabetic sample. In this large population from the ADVANCE study, heart rate showed a strong association with future all-cause mortality, cardiovascular death and major cardiovascular outcomes. PubMedCrossRef • Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia. 2012;55:1283–90. This is the most recent prospective study on the predictive capacity of heart rate for mortality in a diabetic sample. In this large population from the ADVANCE study, heart rate showed a strong association with future all-cause mortality, cardiovascular death and major cardiovascular outcomes. PubMedCrossRef
34.
go back to reference Hillis GS, Hata J, Woodward M, et al. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc. 2012;1:e002832.PubMed Hillis GS, Hata J, Woodward M, et al. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc. 2012;1:e002832.PubMed
35.
go back to reference Barthel P, Bauer A, Müller A. Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction. Diabetes Care. 2011;34:1833–7.PubMedCrossRef Barthel P, Bauer A, Müller A. Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction. Diabetes Care. 2011;34:1833–7.PubMedCrossRef
36.
go back to reference Palatini P, Dorigatti F, Zaetta V, et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens. 2006;24:1873–80.PubMedCrossRef Palatini P, Dorigatti F, Zaetta V, et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens. 2006;24:1873–80.PubMedCrossRef
37.
go back to reference Jouven X, Empana JP, Escolano S, et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol. 2009;103:279–83.PubMedCrossRef Jouven X, Empana JP, Escolano S, et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol. 2009;103:279–83.PubMedCrossRef
38.
go back to reference Paul L, Hastie CE, Li WS, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2010;55:567–74.PubMedCrossRef Paul L, Hastie CE, Li WS, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2010;55:567–74.PubMedCrossRef
39.
go back to reference Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternal VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29:1327–34.PubMedCrossRef Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternal VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29:1327–34.PubMedCrossRef
40.
go back to reference Poulter NR, Dobson JE, Sever PS, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009;54:1154–61.PubMedCrossRef Poulter NR, Dobson JE, Sever PS, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009;54:1154–61.PubMedCrossRef
41.
go back to reference Poulter NR, Dobson JE, Sever PS, et al. Elevated heart rate in hypertension: a target for treatment ? Reply. J Am Coll Cardiol. 2010;55:931–2.CrossRef Poulter NR, Dobson JE, Sever PS, et al. Elevated heart rate in hypertension: a target for treatment ? Reply. J Am Coll Cardiol. 2010;55:931–2.CrossRef
42.
go back to reference Okin PM, Kjeldsen SE, Julius S, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J. 2010;31:2271–9.PubMedCrossRef Okin PM, Kjeldsen SE, Julius S, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J. 2010;31:2271–9.PubMedCrossRef
43.
go back to reference • Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685–92. In this clinical trial performed in a large sample of high-risk hypertensive patients, antihypertensive treatment proved to be effective in subjects with normal heart rate after one year of treatment, but had little effect on the patients with high in-trial heart rate. PubMedCrossRef • Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685–92. In this clinical trial performed in a large sample of high-risk hypertensive patients, antihypertensive treatment proved to be effective in subjects with normal heart rate after one year of treatment, but had little effect on the patients with high in-trial heart rate. PubMedCrossRef
44.
go back to reference Palatini P. Recommendations on how to measure resting heart rate. Medicographia. 2009;31:414–9. Palatini P. Recommendations on how to measure resting heart rate. Medicographia. 2009;31:414–9.
45.
go back to reference Mancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension. 1987;9:209–15.PubMedCrossRef Mancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension. 1987;9:209–15.PubMedCrossRef
46.
go back to reference Palatini P, Winnicki M, Santonastaso M, et al. Reproducibility of heart rate measured in the clinic and with 24-hour intermittent recorders. Am J Hypertens. 2000;13:92–8.PubMedCrossRef Palatini P, Winnicki M, Santonastaso M, et al. Reproducibility of heart rate measured in the clinic and with 24-hour intermittent recorders. Am J Hypertens. 2000;13:92–8.PubMedCrossRef
47.
go back to reference Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004;17:1005–10.PubMed Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004;17:1005–10.PubMed
48.
go back to reference Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777–83.PubMedCrossRef Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777–83.PubMedCrossRef
49.
go back to reference Hansen TW, Thijs L, Boggia J, et al. Prognostic value of ambulatory heart rate revisited in 6928 subjects from 6 populations. Hypertension. 2008;52:229–35.PubMedCrossRef Hansen TW, Thijs L, Boggia J, et al. Prognostic value of ambulatory heart rate revisited in 6928 subjects from 6 populations. Hypertension. 2008;52:229–35.PubMedCrossRef
50.
go back to reference Hozawa A, Inoue R, Ohkubo T, et al. Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study. J Hypertens. 2008;26:1571–6.PubMedCrossRef Hozawa A, Inoue R, Ohkubo T, et al. Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study. J Hypertens. 2008;26:1571–6.PubMedCrossRef
51.
go back to reference Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002;162:2313–21.PubMedCrossRef Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002;162:2313–21.PubMedCrossRef
52.
go back to reference Ben-Dov IZ, Kark JD, Ben-Ishay D, et al. Blunted heart rate dip during sleep and all-cause mortality. Arch Intern Med. 2007;167:2116–21.PubMedCrossRef Ben-Dov IZ, Kark JD, Ben-Ishay D, et al. Blunted heart rate dip during sleep and all-cause mortality. Arch Intern Med. 2007;167:2116–21.PubMedCrossRef
53.
go back to reference • Palatini P, Reboldi G, Beilin LJ, et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol 2013. doi:10.1016/j.ijcard.2012.12.103. This is the most recent study on the predictive capacity of ambulatory heart rate for cardiovascular events. It highlights the better predictive power of heart rate recorded during sleep compared to heart rate measured during waking hours. • Palatini P, Reboldi G, Beilin LJ, et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol 2013. doi:10.​1016/​j.​ijcard.​2012.​12.​103. This is the most recent study on the predictive capacity of ambulatory heart rate for cardiovascular events. It highlights the better predictive power of heart rate recorded during sleep compared to heart rate measured during waking hours.
54.
go back to reference Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–85.PubMedCrossRef Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–85.PubMedCrossRef
55.
go back to reference James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–17.PubMedCrossRef James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–17.PubMedCrossRef
56.
go back to reference Palatini P. Cardiovascular effects of exercise in young hypertensives. Int J Sports Med. 2012;33:683–90.PubMedCrossRef Palatini P. Cardiovascular effects of exercise in young hypertensives. Int J Sports Med. 2012;33:683–90.PubMedCrossRef
57.
go back to reference Blohm D, Ploch T, Apelt S. Efficacy of exercise therapy to reduce cardiometabolic risk factors in overweight and obese children and adolescents: a systematic review. Dtsch Med Wochenschr. 2012;137:2631–6.PubMedCrossRef Blohm D, Ploch T, Apelt S. Efficacy of exercise therapy to reduce cardiometabolic risk factors in overweight and obese children and adolescents: a systematic review. Dtsch Med Wochenschr. 2012;137:2631–6.PubMedCrossRef
58.
go back to reference Palatini P, Visentin P, Dorigatti F, et al. Regular physical activity prevents development of left ventricular hypertrophy in hypertension. Eur Heart J. 2009;30:225–32.PubMedCrossRef Palatini P, Visentin P, Dorigatti F, et al. Regular physical activity prevents development of left ventricular hypertrophy in hypertension. Eur Heart J. 2009;30:225–32.PubMedCrossRef
59.
go back to reference Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–36.PubMedCrossRef Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–36.PubMedCrossRef
60.
go back to reference Grassi G, Trevano FQ, Facchini A, et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press. 2003;2:35–40.CrossRef Grassi G, Trevano FQ, Facchini A, et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press. 2003;2:35–40.CrossRef
61.
go back to reference Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens. 2004;13:513–9.PubMedCrossRef Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens. 2004;13:513–9.PubMedCrossRef
Metadata
Title
Heart Rate and the Cardiometabolic Risk
Author
Paolo Palatini
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 3/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-013-0342-7

Other articles of this Issue 3/2013

Current Hypertension Reports 3/2013 Go to the issue

Blood Pressure Monitoring and Management (J Redon, Section Editor)

Ambulatory Blood Pressure in Chronic Kidney Disease

Hypertension and Obesity (E Reisin, Section Editor)

Obesity and Metabolic Syndrome in Kidney Transplantation

Therapeutic Trials (G Mancia, Section Editor)

Retinal Arterial Hypertrophy: the New LVH?

Blood Pressure Monitoring and Management (J Redon, Section Editor)

Ambulatory Blood Pressure Monitoring in the Prediction and Prevention of Coronary Heart Disease

Blood Pressure Monitoring and Management (J Redon, Section Editor)

Role of Ambulatory Blood Pressure Monitoring in Hypertension and Diabetes

Hypertension and Obesity (E Reisin, Section Editor)

Pharmacologic Treatment Options for Obesity: What Is Old Is New Again

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.